Alexander E Perl, MD
Gilteritinib, a selective tyrosine kinase inhibitor (TKI) against FLT3
, demonstrated a favorable safety profile and consistent FLT3 inhibition in adults with relapsed/refractory acute myeloid leukemia (AML), according to findings recently published in Lancet Oncology
Exposure-related inhibition of FLT3 phosphorylation increased along with increasing gilteritinib concentrations in plasma. Most patients receiving a daily dose of 80 mg or higher had at least 90% of FLT3 phosphorylation inhibition by day 8. In-vivo inhibition of FLT3 occurred at all dose levels.
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18:1061-1075.
... to read the full story